Test Case,Quantitative Performance Score,Quantitative Performance Output,Quantitative Performance Ground Truth,Key Takeaways and Business Updates Output,Key Takeaways and Business Updates Ground Truth,Market Commentary Output,Market Commentary Ground Truth,Extraction Agent Token Usage,Extraction Agent Cost ($),Extraction Agent P95 Latency (ms),Formatting Agent Token Usage,Formatting Agent Cost ($),Formatting Agent P95 Latency (ms),Total Cost ($)
2025_09_Q3_-_Everside_Fund_IV_-_Q3_2025_Quarterly_Update,2.0,"**Quantitative Performance:**   • Net IRR: 11%   • Net MOIC: 1.2x   • Net DPI: 0.03x (3%)   • Since inception (Jun‑2023) through 9/30/25: 11% Net IRR and 1.2x Net TVPI (Q3'25 excerpt)   • Q3'25 snapshot: 11% Net IRR, ~1.1x Net MOIC, 0.03x DPI; 48% of LP commitments called   • Fund distributed $5.8M in Q3'25; total distributions $9.815M; capital called $289.2M of $601M fund   • NAV $312.3M; Total value $322.1M; total portfolio shown: $642.6M (1.1x, 11% IRR)","  • Fund IV generated an 11% Net IRR and 1.1–1.2x Net MOIC / TVPI from inception (June 2023) through September 30, 2025, with Net DPI of ~0.03x (3% of called capital) reflecting the early life of the fund and growing but still modest realizations.   • Performance this quarter was driven primarily by Secondary and Direct investments, which benefit from more seasoned credit profiles and current income, while Primary commitments remain early in their J-curves (~0.9x net MOIC).   • The Fund has called 48% of $601M total commitments and distributed $5.8M in Q3, with management targeting an additional ~2% distribution by year-end 2025.   • Direct portfolio metrics remain conservative, with ~12.7% weighted average coupon, all investments current on interest, and leverage at ~3.8–4.0x, below broader LMM benchmarks.   • Exit momentum is emerging earlier than expected, including a full refinance-driven exit in women’s health (1.2–1.3x net MOIC, ~17% net IRR) and a subsequent full exit in in-home healthcare at similar returns, validating the downside-protected credit-first strategy.","**Key Takeaways and Business Updates:**   • Fund-level Net IRR (11%) exceeded a ~10% blended leveraged-loan/high-yield benchmark   • Net TVPI 1.2x since inception; DPI remains low at 0.03x (3% of called capital)   • Deployment: 48% called, fund ~107% invested (deployment pace vs final close of $601M)   • Realizations beginning to materialize: first full exit in‑quarter and second full exit post‑quarter   • Expecting an income distribution ~2% of called capital by end of Q4'25   • Secondary sleeve outperformed direct sleeve (32% IRR / 1.2x vs direct 12% IRR / 1.1x)","  • Underwriting emphasized Secondaries and Directs to reduce early J-curve drag; this is playing out, with Secondaries and Directs driving nearly all current performance and cash yield while Primaries remain early.   • Fund IV has outperformed a blended high-yield and leveraged loan benchmark (~10%) despite early-stage drag from Primary investments, underscoring the value of the diversified Primary / Secondary / Direct structure.   • Our underwriting highlighted that DPI would lag peers early due to SBIC structure; current DPI profile is fully consistent with this known risk and not indicative of underperformance. DPI focus is increasing, with management explicitly highlighting improved M&A conditions, rising strategic buyer interest, and multiple portfolio companies entering sale processes, which should support faster distribution velocity in 2026.   • Portfolio fundamentals remain strong, with LTM revenue up ~7.6% and EBITDA up ~5.6%, and no evidence of systemic credit stress across holdings.","**Market Commentary:**   • M&A activity reaccelerated in Sept‑2025; portfolio companies attracting sale processes and unsolicited bids   • Q3'25 activity: one new primary, three new direct investments, and first full portfolio exit closed   • After quarter: large secondary acquired ($17M), an additional direct investment, and second full exit completed   • Notable new commitments: $25M primary to SBIC fund; direct deals include $2.6M pest control, $6.5M convertible preferred (ABA/rehab), $2.9M event rentals   • Team additions made to investment, data, accounting, and IR support functions","  • M&A activity accelerated meaningfully starting September 2025, supported by pent-up demand following rate cuts and renewed engagement from both private equity and well-capitalized strategic buyers moving down-market.",31023,0.0832,48713.92,4736,0.0043,50011.38,0.0875
2025_09_Q3_-_Silver_Lake_VII_-_Q3_2025_Quarterly_Performance_Update_(1),2.0,"**Quantitative Performance:**   • Net IRR: 13.9%   • Net MOIC: 1.21x   • Net DPI: 0.1%   • Fund-level Net IRR: 13.9% (as of 9/30/25)   • Fund-level Net MOIC: 1.21x (as of 9/30/25)   • Fund-level Distributions / Total paid-in capital (DPI): 0.1% (as of 9/30/25)   • Fund NAV: $21,123,807 (as of 9/30/25)   • Total investment commitments: $55,133,000 (as of 12/8/25)   • Investment commitment called: 38.3% (as of 9/30/25)   • Last investment capital call: effective 9/19/25, 5th call of $2.0M (3.7% of committed)   • Last distribution: effective 1/2/25, 1st distribution $19K (0.1% of contributed capital)   • Average age of remaining portfolio: 1.1 years (as of 9/30/25)","  • Net IRR: 15.7% (Fund level), 13.9% (for a $500K advisory investor)   • Net MOIC: 1.21x (Fund level), 1.18x (for a $500K advisory investor)   • DPI (Distributions / Paid-in Capital): 0.1%   • NAV as of 9/30/25: $25.44M   • Total Commitments: $55.1M   • Funded Commitments (net of recallables): $21.1M (38.3%)   • Total Paid-in Capital: $21.1M   • Total Distributions: $19K (first distribution, effective 1/2/25)   • Average Age of Remaining Portfolio: 1.1 years   • Underlying Fund (SLP VII) Net MOIC: 1.31x; 34.5% funded   • Number of Investments: 8 (all unrealized)   • Public Investments: None",**Key Takeaways and Business Updates:**   • Fund-level performance: 13.9% Net IRR and 1.21x Net MOIC (9/30/25)   • Early distribution profile: DPI 0.1% (9/30/25)   • 38.3% of commitments called; remaining portfolio average age 1.1 years   • Underlying fund highlighted: Silver Lake Partners VII (2023 vintage) Net MOIC 1.31x; 34.5% called (9/30/25),"  • The fund is in early deployment stages with only 38.3% of capital called to date and limited distributions (0.1% DPI), which is expected for a 2024 vintage   • Fund performance shows solid early value creation, with a Net MOIC of 1.21x and Net IRR of 15.7%, outperforming typical benchmarks at this point in the fund lifecycle   • Investment activity is diversified across a range of industries with a heavy concentration in technology (63%)   • The portfolio is fully unrealized, and investors should expect continued capital deployment and value build-up over the next 12–24 months   • Investments in high-growth tech and infrastructure platforms (e.g., Qualtrics, Vantage Data Centers, Altera) are showing promising early unrealized MOICs   • Top 8 investments represent 100% of current portfolio fair value, concentrated across U.S. and UAE assets",**Market Commentary:**   • Altera: Silver Lake acquired 51% from Intel; headline TEV $8.75B (closed 9/12/25); SLP VII-funded ~ $1.2B; Altera unrealized gross MOIC 1.20x (9/30/25)   • Endeavor/TKO: secured multi-year media rights renewals; >$180M run-rate cost savings; Events divestment expected close Q4 2025 to prepay debt; unrealized gross MOIC 1.73x (9/30/25)   • PowLan: SLP VII invested $9M in Q3 2025; unrealized gross MOIC 1.10x (9/30/25)   • Qualtrics: Oct 2025 agreement to acquire Press Ganey Forsta ($6.75B EV); funded without new cash equity; unrealized gross MOIC 1.41x (9/30/25)   • Vantage Data Centers: additional capital including $165M from SLP VII in Q3 2025; SLP VII funded ~$826M (NA) and ~$677M (EMEA); unrealized gross MOIC 1.51x (9/30/25),"  • Qualtrics (29% of portfolio fair value) agreed to acquire Press Ganey Forsta for $6.75B in a strategic deal using internal cash, debt, and equity. This strengthens its position in the AI-powered experience management market. As of 9/30/25, Qualtrics had a MOIC of 1.41x   • Mission Pet Health (19.2% of fair value) and Vantage Data Centers (17.2%) continue to be top holdings. Vantage has received new capital to support 2.3GW hyperscale data center leases; current MOIC stands at 1.51x   • Endeavor Group Holdings (12.1%) benefited from significant media rights renewals for UFC ($7.7B) and WWE ($1.6B), exceeding expectations and unlocking cost synergies post take-private. As of Q3, MOIC was 1.73x   • Altera (11.3%) was acquired in partnership with Intel (Silver Lake took a 51% stake). The deal closed in September 2025; early MOIC is 1.20x   • PowLan (newer, small position) is supporting proprietary powered land for data centers, co-sponsored with Commonwealth AM. MOIC at 1.10x   • The portfolio remains entirely U.S.-centric (95%) with a small UAE allocation (Khazna Data Centers)   • Silver Lake continues to focus on digital infrastructure, enterprise software, and vertical tech platforms, deploying capital methodically across growth opportunities with platform potential",7164,0.0232,48713.92,3129,0.0032,50011.38,0.0264
2025_12_Q4_-_Newfront_-_Acquisition,3.0,"**Quantitative Performance:**   • Net IRR: Not reported   • Announced acquisition by Willis Towers Watson (Nasdaq: WTW) for up to $1.3 billion   • Upfront consideration of $1.05 billion (≈ $900M cash, $150M equity) to Newfront employee-shareholders   • Contingent consideration up to $250 million payable primarily in equity subject to performance targets   • Incremental up to $150 million (primarily equity) payable if above-target revenue growth is achieved   • Transaction expected to close in Q1 2026 subject to regulatory approvals and customary closing conditions   • Manager indicates outcome expected to return entire principal to investors; final distribution mechanics pending cash flow waterfall","  • $1.05 billion upfront, consisting of:   • ~$900M in cash   • ~$150M in equity for Newfront employee-shareholders   • Up to $250M in contingent equity consideration based on performance targets   • Additional $150M earnout (primarily equity) tied to above-target revenue growth.   • Investors will receive a return of principal. Final cash flow waterfall is pending; full mechanics and timing of distributions will follow.",**Key Takeaways and Business Updates:**   • Exit announced at up to $1.3 billion headline value with a mix of cash and equity consideration   • Base consideration of $1.05 billion with additional earnout components up to $400 million tied to performance/revenue growth   • Closing targeted for Q1 2026; timing and amounts of distributions not yet provided (awaiting final cash flow waterfall),"  • The exit provides a full return of capital to investors ahead of expectations, despite the company not meeting earlier revenue growth hopes.   • While the investment did not generate outsized returns, it did produce capital preservation and liquidity in a challenging private market environment.   • This outcome reflects the strategic value of Newfront’s proprietary software, which drew interest from a large incumbent.",**Market Commentary:**   • Strategic buyer: Willis Towers Watson acquiring Newfront   • Rationale: Newfront's differentiated technology offerings and strategic interest from industry incumbents   • Manager commentary notes revenue growth in recent years was slower than hoped relative to entry valuation,"  • The transaction validates Newfront’s tech-enabled approach to insurance brokerage, which had long been considered attractive to strategic buyers.   • Transaction expected to close in Q1 2026, subject to regulatory approvals and customary closing conditions.   • Investors will be updated once the final distribution details are provided by company counsel.",1739,0.0076,48713.92,2071,0.0020,50011.38,0.0095
2025_09_Q3_-_Silver_Lake_VI_-_Q3_2025_Quarterly_Performance_Update_(1),3.0,**Quantitative Performance:**   • Net IRR: 7.1% (vs benchmark 13.1% - Bottom 25%)   • Net MOIC: 1.22x (vs benchmark 1.28x - Below Median)   • Net DPI: 0.131x (vs benchmark 0.46x - Bottom 10%)   • 09/30/2025 NAV $316.2M; net MOIC 1.22x; net IRR 7.1% (fund level)   • Paid-in capital $289.7M; distributions $37.8M; distributions / paid-in = 13.1%   • 12/04/2025: total commitments $269.9M; funded less recallable $236.85M (87.8% funded)   • 09/30/2025 underlying commitments $265.3M; 87.5% funded; MOIC 1.29x; 57 investments (49 remaining; 8 public),"  • Fund-level performance as of 9/30/2025:  – Net IRR: 7.1%  – Net MOIC: 1.22x  – Net DPI: 13.1%   • Total commitments: $269.9M; Funded commitments (net of recallables): $236.8M (87.8%)   • NAV: $316.2M as of 9/30/2025   • Distributions to date: $37.8M   • Portfolio includes 57 investments, with 49 remaining, 8 of which are public   • Underlying fund MOIC: 1.29x (Silver Lake Partners VI and Silver Lake Alpine II combined)   • SLP VI individual MOIC: 1.29x (94.2% funded)   • Average age of remaining portfolio: 3.8 years   • Most recent capital call (22nd): $4.1M on 9/30/25 (1.5% of committed capital)   • Most recent distribution (9th): $1.7M on 9/30/25 (0.6% of contributed capital)   • Top 10 investments comprise 53.6% of total fair value   • Geographic allocation (by remaining value): 55% U.S., 10% U.K., 7% Italy, 7% UAE, 6% France   • Sector exposure (by remaining value): 66% Information Technology, 14% Consumer Discretionary, 7% Communications Services, 6% Healthcare, 4% Financials, 3% Industrials","**Key Takeaways and Business Updates:**   • Fund-level net performance: 7.1% IRR, 1.22x MOIC (09/30/2025)   • DPI implied by distributions/paid-in = 0.131x (13.1%)   • Fund 87.8% funded (as of 12/04/2025)   • 9/30/25 capital call: 22nd, $4.1M (1.5% of committed capital)   • 9/30/25 distribution: 9th, $1.7M (0.6% of current contributed capital)   • Top 10 investments = 53.6% of total NAV (09/30/2025)","  • Fund continues to demonstrate moderate growth with a net IRR of 7.1% and net MOIC of 1.22x, consistent with prior quarters and in line with a maturing growth equity portfolio   • Distributions remain modest at 13.1% DPI, signaling the majority of returns are unrealized and the portfolio is still in value-building mode   • Strong unrealized performance in select positions: Clubessential (2.32x MOIC), Shadowbox/Powlan (1.62x), Vantage Data Centers (1.51x), and Qualtrics (1.24x), highlighting embedded value in portfolio.   • Portfolio composition remains heavily weighted to IT (66%), with a global footprint primarily centered in the U.S. but diversified across EMEA as well.","**Market Commentary:**   • Clari (SLP VI): merged with Salesloft (agreement 8/7/25; closed Q4); SLP VI to receive ~ $13M dividend; unrealized gross MOIC 0.81x   • Klarna (SLP VI): sold 2.4M shares in Sep 2025 IPO (15% position); $91M proceeds at $38.30 vs $37.75 cost; unreal. MOIC 0.98x   • Qualtrics (SLP VI): signed to acquire Press Ganey Forsta (Oct 2025); financed with cash/debt/equity; unreal. MOIC 1.24x   • Shadowbox Studios / Powlan (SLP VI): $12M funded Apr–Jul 2025; cumulative $21M; unreal. MOIC 1.62x   • Vantage Data Centers (SLP VI): Silver Lake elected additional $602M (Sep 2025); SLP VI funded $364M to 09/30/25; remaining unfunded in Vantage NA $1,186M; unreal. MOIC 1.51x   • Clubessential (SLA II): agreed sale to Xplor (Q3 2025) at $3.25B TEV; expected ~60% cash monetization, ~40% roll; pending approvals; unreal. MOIC 2.32x","  • Clari merger with Salesloft (Q4 2025 close) created a 50/50 combined entity; Silver Lake to receive ~$13M dividend from pre-merger Clari cash—Clari’s MOIC at 0.81x as of Q3   • Klarna IPO (NYSE) – Silver Lake sold 15% of its position for $91M proceeds, slightly above cost basis ($38.30/share vs. $37.75/share); MOIC of 0.98x as of Q3   • Qualtrics acquisition of Press Ganey Forsta ($6.75B TEV) with no new equity required—position well-positioned in the AI/experience analytics space; MOIC at 1.24x   • Shadowbox Studios / Powlan – $12M incremental funding brings total to $21M; MOIC at 1.62x; plays in film infrastructure and hyperscale data support sectors   • Vantage Data Centers – Additional $602M committed, with $364M funded as of Q3; MOIC of 1.51x; Silver Lake retains substantial upside via unfunded commitments   • Clubessential pending sale to Xplor Technologies – Monetization of ~60% stake in cash, 40% roll into new entity; deal values company at $3.25B; MOIC at 2.32x   • Overall activity reflects a gradual shift toward realization, with partial exits and M&A providing signs of maturing investments and potential DPI acceleration in future quarters   • Fund remains aligned with strategy to back high-growth, tech-enabled platforms across vertical software, fintech, infrastructure, and healthcare tech",8254,0.0258,48713.92,4161,0.0049,50011.38,0.0307
2025_11_Q4_-_Satori_Alpha_II_-__November_2025_Update_(1),3.0,"**Quantitative Performance:**   • Net IRR: Not provided   • Net MOIC: Not provided   • Net DPI: Not provided   • Satori Power: cumulative net return 79.77% since launch (Feb 2022–Nov 2025)   • Benchmark comparison since launch: Blended Sector +27.02%; S&P 500 +60.63%   • Liquid investments table includes Nov-25, YTD, 2024, fund ITD annualized return and Satori ITD return (net of underlying fees and Satori hypothetical fees: 1.4% mgmt / 10% incentive)   • Bounty Minerals: 3Q revenue $30.2M and EBITDA $25.2M (23% QoQ); 9M EBITDA $69.7M (+97% YoY)   • X-Energy: subsequent fundraising at $5.0B pre-money vs prior $1.1B","  • Fund-level Net IRR, Net MOIC, and Net DPI are not provided in the November 2025 update, as Satori Alpha II combines liquid and illiquid strategies and does not calculate an aggregate fund-level performance metric across both.   • Liquid investments within Satori Alpha portfolios showed generally strong performance through November 30, 2025, with several core managers delivering double-digit YTD and ITD annualized returns net of underlying fees and Satori Alpha’s hypothetical fund-level fees.",**Key Takeaways and Business Updates:**   • Fund-level Net IRR/MOIC/TVPI/DPI not disclosed in this update   • Satori Power materially outperformed its blended sector benchmark (79.77% vs 27.02%)   • Bounty Minerals showing strong profitability and material EBITDA growth   • Crescent/GPIF hospitality assets experienced significant write-downs (two properties marked to zero; others down 17.5% in 3Q)   • Document largely contains disclosures/definitions and does not report aggregate fund performance metrics,"  • The portfolio continues to benefit from strong manager selection across liquid equity and credit strategies, with notable contributions from RA Capital, Pershing Square, Pavise, and Regan Credit platforms.","**Market Commentary:**   • Added ""Private Distribution Summary"" to highlight recent distributions from underlying managers and co-invests   • November distributions: Aqua Ceres Australia Water Fund (water credits sale), Bounty Minerals (OFCF), Cicero HUD Loans I (operating income), Glade Brook Strategic Growth III (partial sale of Zepto)   • Crescent/GPIF: Kimpton Brice Savannah and Kimpton Monaco Denver marked to zero; Hotel Crescent Court and Ritz-Carlton Dallas down 17.5% in 3Q; exploring sale of Hotel at Avalon and a secondary recap for a hotel pool   • Crescent expects strong multifamily realizations in 1H 2026 and sees potential tailwind from 2026 FIFA matches   • X-Energy: accelerated NRC review, broke ground on U.S. advanced nuclear fuel facility, secured major partnerships and mobilized up to $50B of capital with Amazon and partners   • New commitments planned: Satori to commit to Zelda Ventures II (target late Jan) and expects to add Glade Brook Strategic Growth V (target finalize end of 1Q 2026)","  • X-Energy, a core private holding, completed a significant up-round at a $5 billion pre-money valuation (up from $1.1 billion), advanced regulatory approvals, broke ground on the first advanced nuclear fuel facility in the U.S., and secured large-scale global partnerships alongside Amazon and international investors.   • Bounty Minerals continues to demonstrate strong operating momentum, reporting $30.2 million of Q3 revenue and $25.2 million of EBITDA, with year-to-date EBITDA up 97% year-over-year, supported by LNG exports and longer-term AI-driven power demand.   • Crescent / GPIF reported mixed hospitality performance with select assets marked down to zero, but remains optimistic about realizations over the next 12–18 months and sees potential demand tailwinds from the 2026 FIFA World Cup.   • Satori plans to expand the platform with new commitments, including Zelda Ventures II and Glade Brook Strategic Growth V, reinforcing continued access to high-quality venture and growth equity opportunities as AI reshapes global industries",9281,0.0299,48713.92,3320,0.0033,50011.38,0.0332
2025_09_Q3_-_Riverside_Vargas_(BWE)_-_Q3_2025_Report,3.0,"**Quantitative Performance:**   • Net IRR: N/A (direct investment; early-stage development)   • Construction commenced; Notice to Proceed issued to Skybeck on 9/8/2025; site prep and earthwork underway   • Construction loan closed with IBC Bank on 9/5/2025: $56,458,899 at 55% loan-to-cost   • Interest rate: floating at NY Prime (7.25% as of 9/30/2025) with step-down floor (7.25% / 6.75% / 6.25%)   • Development budget (9/30/2025): $102,652,544; costs to date $24,340,561 (23.71%); remaining $78,311,983 (76.29%)   • General Contractor GMP (Skybeck): $64,475,027; approved OCOs to date: $0   • Hard costs paid through 9/30/2025: $1,564,180 (2.43% of hard costs)   • Remaining contingency (9/30/2025): hard cost $1,647,162; project $4,049,455; total $5,696,617   • Construction timeline targets first unit delivery October 2027 and final close-out February 2028","  • Riverside Vargas (BWE) is an early-stage development investment; as of Q3 2025 there are no fund-level Net IRR, Net MOIC, or Net DPI metrics available, as the project has not yet begun operations or generated cash flow.   • Total equity at the GP QOF level is $2.63 million, fully funded by Class A investors, representing a 5.59% ownership interest in the underlying Riverside–Vargas QOZB Condo 1, LLC as of September 30, 2025.   • The overall development budget totals $102.7 million, with $24.3 million (23.7%) spent to date and $78.3 million remaining, indicating the project is still in the early construction phase.   • A $56.5 million construction loan has closed at 55% loan-to-cost, providing sufficient leverage to carry the project through development with contingencies fully intact.",**Key Takeaways and Business Updates:**   • Major milestone: broke ground and began site work following NTP (9/8/2025)   • Permitting progress: site development permit approved/pulled; building permit fees paid and permit pulled   • Financing secured: $56.46M construction loan at 55% LTC with floating prime-based rate (7.25% as of 9/30/2025)   • Project spend tracking: 23.71% of total development budget incurred as of 9/30/2025   • Contingency remaining totals $5.70M as of 9/30/2025,"  • The investment has successfully transitioned from pre-development to active construction, materially reducing entitlement and execution risk following permit approvals and loan closing.   • With construction just underway and no income generation yet, performance should be evaluated primarily on milestone achievement and budget adherence, both of which are currently tracking as planned.   • The GMP with Skybeck remains unchanged at $64.5 million, with no approved change orders to date, supporting cost certainty at this stage of development.   • Significant remaining contingency ($5.7 million total) provides downside protection against construction cost inflation or unforeseen issues during the build phase.","**Market Commentary:**   • Project rebranded from Riverside–Vargas to ""The Grant""; branding updates and renderings to be shared in future investor communications   • Easements and license agreements are nearing completion   • Construction schedule established: first units October 2027; final close-out February 2028","  • Construction officially commenced on September 8, 2025, following issuance of the Notice to Proceed to Skybeck, with site preparation and earthwork now underway at the Austin Riverside location.   • All major site development and building permits have been secured, and nearly all easements and license agreements have been finalized, clearing key regulatory hurdles.   • The project has been rebranded as “The Grant”, with updated branding and marketing materials to be shared in future investor updates, supporting future lease-up positioning.   • The current construction schedule targets first unit delivery in October 2027 and final close-out by February 2028, setting expectations for a longer-duration, development-oriented investment profile.",3421,0.0132,48713.92,3128,0.0037,50011.38,0.0168
2025_09_Q3_-_Kaia_Residences_(BWE)_-_Q3_2025_Report,3.0,"**Quantitative Performance:**   • Net IRR: No fund-level net IRR reported (direct investment; forward-looking Class C estimates only)   • Construction progress: superstructure concrete nearing completion on Level 2 (Q3 2025)   • Construction start/schedule: began Apr 2025; 29.9% shown on development schedule   • Budget: total current budget $161,460,608; 16.8% drawn to date   • Tariff exposure: $0.8M–$1.2M (unchanged; within contingency)   • Schedule impact: ~2-month shift from Xcel Energy delay; substantial completion projected mid‑Q4 2027   • Market rents (Q3 2025, high-end): ~$3,577/unit (~$3.35/SF); -3.2% QoQ, -4.4% YoY   • Denver metro rents: -4.9% YoY (steepest annual decrease in >20 years)   • Leasing: 12,598 units absorbed over past year (robust absorption)   • Debt snapshot: Bank OZK (mortgage) & Affinius Capital (mezz); construction loan limit $111,450,000; outstanding balance $0 as of 9/30/2025; rate SOFR+4.35% (3.75% floor & cap)   • Capital calls completed: 25% (Nov), 22% (May), 26.5% (Aug), 26.5% (Nov) per updated schedule   • Remaining unfunded equity: ~ $10.1M (29.7% of commitments) due by Nov 30, 2025",,"**Key Takeaways and Business Updates:**   • No fund-level net IRR/MOIC/DPI reported; only forward-looking Class C estimates provided   • Project budget remains consistent; tariff exposure unchanged and within contingency   • Schedule pushed ~2 months; substantial completion now targeted mid‑Q4 2027   • High-end rent comps declined (-3.2% QoQ; -4.4% YoY) but absorption remains strong (12,598 units), suggesting market stabilization   • Construction financing in place with $111.45M limit and $0 outstanding as of 9/30/2025","  • The original underwriting assumed a 52-month hold with ~28 months of construction; current timelines now reflect a ~2-month schedule delay, pushing substantial completion to mid-Q4 2027, modestly behind plan but not yet threatening the targeted 2029 disposition window. Development economics remain intact despite schedule pressure, with the sponsor indicating tariff-related cost exposure of $800K–$1.2M, unchanged from Q2 and fully absorbed within existing contingency.   • Total project budget remains consistent with underwriting, supported by a GMP contract, and there have been no budget overruns to date, aligning with the memo’s emphasis on construction cost certainty.   • Approximately 29.7% of total equity commitments (~$10.1 million) represented the final unfunded tranche, with the last capital call due by November 30, 2025, completing the equity funding plan.   • Balance sheet growth is tracking construction progress, with work-in-progress assets increasing to ~$35.1M, up materially quarter-over-quarter, while cash balances remain strong at the property level.   • Near-term financials show expected operating losses and zero revenue, consistent with a pre-lease-up development phase and no indication of budget overruns or financing stress.   • Construction risk is tracking slightly worse than initial expectations due to a third-party utility delay (Xcel Energy), but this risk was explicitly contemplated in the underwriting and mitigated through contingency, GMP structure, and sponsor control over sequencing and labor.   • The investment memo underwrote strong rent growth (4.6% avg.) driven by supply constraints, whereas actual market data shows short-term rent declines (-4.4% YoY for luxury Denver), representing the largest negative deviation from original expectations. Below expectations in near-term market rents, but with improving absorption dynamics that support the medium-term lease-up thesis. The regulatory-tailwind thesis remains fully intact: Kaia’s exemption from Denver’s affordable housing ordinance continues to limit competitive supply, and no new contrary regulatory risks have emerged.","**Market Commentary:**   • River City evaluating schedule acceleration via additional manpower and concurrent trade activity   • Recovery options under review: increased labor, overtime, and sequencing adjustments to mitigate delay   • Denver rent environment weakening (metro -4.9% YoY) while leasing/absorption remains strong per market report   • Project: 295-unit Class A+ high-rise with ground-floor commercial space at 808 N Lincoln St., Denver (Golden Triangle)","  • Denver high-end luxury apartment rents averaged $3,577 per unit ($3.35 PSF) in Q3 2025, reflecting a 3.2% quarter-over-quarter and 4.4% year-over-year decline, while the broader Denver metro experienced a 4.9% YoY rent decline, the steepest in over 20 years.   • Return sensitivity remains intact: while near-term market rents are below the memo’s pro forma assumptions, the project remains early enough that long-term IRR math is still driven more by stabilization timing and exit cap rates than by current spot rents.",5855,0.0190,48713.92,3678,0.0046,50011.38,0.0236
2025_09_Q3_-_Peregrine_Select_Fund_II_-_Q3_2025_LP_Report,3.0,"**Quantitative Performance:**   • Net IRR: Not provided   • Net MOIC: 1.32x (vs benchmark 1.08x - Top 25%)   • Net DPI: 0.00x (vs benchmark 0.0x - Above Median)   • Net Performance (post all fees): TVPI 1.32x   • DPI reported 0.00x (value largely unrealized)   • Capital committed/called: $43,020,000 / $43,020,000; partners’ residual capital balance $57,233,207   • Portfolio summary (Q3 2025): total cost ~$37.8M, total value ~$59.3M (multiple 1.57x); total investments at cost $37.15M, fair value $59.26M; unrealized gain ~$22.11M   • Q3 marked net increase: 2 markups vs 4 markdowns; quarter net unrealized gain ~$4.80M; YTD net income $(2.37)M","  • Total Committed Capital: $43.02M   • Capital Called: $43.02M   • Distributions to Date: $0   • Net TVPI: 1.32x   • Net DPI: 0.00x   • Accrued Carry Fees: $2.88M   • Partners’ Residual Capital Balance: $57.2M   • Net Q3 2025 Income: $4.58M, driven by unrealized gains of ~$4.8M   • Highest performing position:   • Precision Medication: $1.45M cost → $16.31M value (11.25x MOIC)   • Other notable positions:   • Benefitbay: $2.6M cost → $5.16M value (1.98x MOIC across tranches)   • Elife: $3.5M cost → $6.84M value (1.95x MOIC)   • Revi: $1.25M cost → $3.0M value (2.4x MOIC overall)   • Total unrealized gain: $22.1M on a $37.2M cost basis across portfolio","**Key Takeaways and Business Updates:**   • Fund-level TVPI 1.32x with 0.00x DPI—value is mainly unrealized to date   • Q3 marks: Precision Medication largest markup (value $16.31M on $1.45M cost, ~11.25x)   • Notable impairments: Vertify and Unboxt marked to $0; ForwardLane down to 50% of cost   • Significant unrealized appreciation: ~$22.11M gain on ~$37.15M cost (as of 9/30/25)   • Performance driven by unrealized marks; watch list includes Cadalys, Maya AI, Averi, Eze","  • Portfolio saw two material Q3 markups (Precision Medication, Revi) and four markdowns (including Benefitbay and Stage Meta), with overall net unrealized gain of ~$4.8M in Q3.   • Benefitbay and HelloHero received follow-on investments in Q3.   • No cash distributions yet, but the portfolio has significant upside potential, especially from positions like Precision Medication and Benefitbay.   • Precision Medication rebounded sharply after halting GLP-1 compounding (formerly 70%+ of revenue). It is now EBITDA positive and has a clear runway to dominance in the D2C compounding space.","**Market Commentary:**   • Follow-on activity: Q3 follow-ons into Benefitbay and HelloHero   • Benefitbay: position down to $5.16M from $6.28M; company value $50M; ended Q3 with ~$7M contracted ARR; expects ~10M contracted ARR by year-end (most go-live Jan 2026)   • Precision Medication: marked up to $16.31M; stabilized ~ $45M revenue run-rate; near breakeven; facility expansion and credit line discussion   • Upswot asset sale closed Jan 2025 (stock consideration, holdback and potential earnout)   • HAAS Alert closing $3M–$4M Series A extension; burn reduction to extend runway through 2026   • Influence Mobile: right-sized team, launched AI bidding engine, expanded financing round to $2M; product metrics improving","  • Overall portfolio quality improving, with several companies nearing inflection points or successfully executing pivots.   • Liquidity events:   • Upswot sold to Uptiq; conversion into equity with ~25% of proceeds in holdback.   • Qeepsake executed an all-stock asset sale to Tinybeans; proceeds expected post 24-month lockup.   • Macro environment still poses challenges, but many portfolio companies are adapting by shifting to cash-flow positive operations or raising insider-led rounds at reasonable valuations.   • GPs remain actively involved, especially in distressed or pivoting companies, with hands-on support through capital raises, restructurings, and GTM strategies.",21424,0.0796,48713.92,6168,0.0049,50011.38,0.0845
2025_09_Q3_-_CD&R_-_Q3_2025_Quarterly_Performance_Update,1.0,"**Quantitative Performance:**   • Net IRR: 6.1% (vs benchmark 13.03% - Below Median)   • Net MOIC: 1.2x (vs benchmark 1.11x - Top 25%)   • Net DPI: 0.0x (vs benchmark 0.06x - Bottom 25%)   • As of 9/30/2025 Fund XI net MOI 1.2x (unchanged vs prior quarter)   • As of 9/30/2025 net IRR 6.0% unlevered / 6.1% levered   • Fund size $15,249.4mm; Q-end total value $16,674.0mm (+5.5% Q/Q); capital called 87%; invested capital $12,494.7mm; realized value $391.0mm   • Total Fund XI (including leverage): 1.3x MOIC and 10.0% IRR; Schedule of Investments shows ~1.3x MOIC / ~8.6% IRR (summary)","  • Net IRR: 15%   • Net MOIC: 1.2x   • Net DPI: 0.1x   • Total Value: $4.6B (includes $0.4B of distributions and $4.2B of NAV)   • 12 investments completed, 66% of capital committed   • Net IRR: 21%   • Net MOIC: 2.0x   • Net DPI: 0.7x   • Total Value: $13.5B (includes $5.1B of distributions and $8.4B of NAV)   • 17 investments completed, 98% of capital committed   • Net IRR: 28%   • Net MOIC: 2.6x   • Net DPI: 1.8x   • Total Value: $8.4B (includes $5.8B of distributions and $2.6B of NAV)   • All investments realized or partially exited   • Net IRR: 20%   • Net MOIC: 2.3x   • Net DPI: 2.3x   • Fully realized with $4.8B of total distributions",**Key Takeaways and Business Updates:**   • Fund-level net performance: ~1.2x Net MOIC and ~6.0–6.1% Net IRR; net DPI remains 0.0x   • Q-end total value increased to $16.674bn (+5.5% Q/Q); portfolio momentum improving with fewer detractors   • White Cap = standout realized performance (5.0x MOIC; 49.9% IRR)   • MCC (Multi-Color) identified as challenged; transformation and balance-sheet restructuring underway   • Indicor: refinancing enabled $224M returned (2.5x MOI) and shows revenue/EBITDA growth with modest margin compression   • Vialto: deleveraging achieved (net debt down ~$504M); recapitalization completed Feb 2025,"  • Fund XI is still early in its deployment cycle, with just over two-thirds of capital committed and moderate early performance, suggesting a long runway for value creation ahead.   • Fund X is progressing strongly, showing meaningful value creation across its portfolio with a solid balance of NAV and DPI.   • Fund IX’s performance remains robust with strong realizations contributing to high DPI and MOIC figures; most of the value has already been returned to investors.   • Fund VIII is fully exited and has returned all capital plus gains, rounding out its lifecycle with a 2.3x MOIC and solid returns through different market cycles.   • Portfolio NAV for all active funds reflects a conservative valuation policy and performance supported by both operational improvements and strategic exits.   • Continued emphasis on sector expertise (industrials, healthcare, consumer/retail, and services) supports performance stability amid macro uncertainty.","**Market Commentary:**   • Sharp closed $319mm shareholder distribution in Oct 2025; Fund XI received $157mm used to repay subscription line   • Sharp refinancing raised net leverage to 6.0x but reduced cost of debt and extended maturities   • Gentiva, Indicor and Inizio advancing cost/growth initiatives; Pursuit Aerospace benefiting from robust demand   • Vialto pursuing AI-enabled efficiency (Project Vanguard) and other margin initiatives after recapitalization   • Morrisons: modest like‑for‑like topline growth, significant debt reduction and medium‑term cost/working‑capital targets","  • CD&R notes a challenging macroeconomic backdrop including persistent inflation, interest rate volatility, and geopolitical instability, though deal flow has begun to recover from 2022–2023 lows.   • The firm has maintained disciplined underwriting and a value orientation, citing advantages in operational improvement as a key differentiator in driving portfolio performance.   • Exit activity is expected to increase going into 2026 as several portfolio companies mature and market conditions stabilize, particularly for IPOs and strategic sales.   • There is cautious optimism around the market environment, with CD&R citing early signs of a more constructive fundraising and exit landscape compared to recent quarters.   • Fundraising for the next vintage is likely to begin in 2026, supported by strong performance in prior funds and a differentiated sourcing and value creation strategy.",63439,0.1821,48713.92,8140,0.0055,50011.38,0.1876
2025_09_Q3_-_SpaceX_(Zanbato_Partners_Fund)_-_Q3_2025_Investment_Report_-_SEGIT_(Grojean)_(1),3.0,"**Quantitative Performance:**   • Net IRR: Not provided   • Net MOIC: Not provided   • Net DPI: Not provided   • Q3 2025 capital account balance: $367,878.47   • Invested capital / total paid-in capital: $142,884.00   • Realized proceeds: $0.00   • % gain (TTM): 121.42% (net of management fees and expenses)   • % gain (all time): 157.47% (net of management fees and expenses)","  • Capital Account Balance (Q3 2025): $367,878.47   • Total Paid-in Capital: $142,884.00   • Invested Capital: $142,884.00   • Realized Proceeds: $0.00   • % Gain (Trailing 12 Months): 121.42%   • % Gain (All Time): 157.47%   • Issue Date: October 19, 2023   • Valuation Change: Share price rose from $81.00 (Sep 2023) to $212.00 (Aug 2025), reflecting a post-money valuation increase from $150B to $400B",**Key Takeaways and Business Updates:**   • Performance presented as % gain based on capital account change (net of fees/expenses); fund-level Net IRR/MOIC/DPI not provided   • No realizations to date (realized proceeds: $0.00)   • Latest tender indicates underlying company post-money valuation of $400B at $212.00/share (Aug 2025),"  • Capital account value more than doubled since investment initiation, driven by sustained growth in SpaceX’s valuation across multiple tender offers   • Over the trailing 12 months, investor capital appreciated 121%, with 157% total gain since October 2023   • Investment remains fully unrealized, with no liquidity events or cash distributions recorded yet   • Latest secondary market tender priced SpaceX at $212/share, implying a $400B post-money valuation, the highest to date   • Rapid appreciation reflects strong private market demand and increasing strategic value of SpaceX's core businesses (launch, Starlink, and direct-to-cell connectivity)","**Market Commentary:**   • SpaceX sustained a record launch cadence through Q3 2025   • Aug 26: Starship 10th test flight completed first in-space payload demonstration, deploying eight Starlink simulators and advancing heat‑shield and propulsive‑reentry objectives   • Starlink reportedly topped 7 million users in August and supports customers across 150 countries   • T‑Mobile Starlink-powered Direct-to-Cell text service began U.S. rollout in July   • SpaceX purchased wireless spectrum licenses from EchoStar for $17bn to support direct-to-cell service on owned frequencies   • Tender history (post-money valuations): Sep 2023 $150B; Apr 2024 $180B; Jul 2024 $210B; Dec 2024 $350B; Aug 2025 $400B","  • Starship Milestone: On August 26, SpaceX completed its 10th Starship test flight, successfully deploying eight Starlink simulator payloads in orbit. This marked the first in-space payload deployment and achieved key progress in heat-shield and propulsive reentry validation   • Starlink Expansion: Reported over 7 million users across 150 countries as of August 2025, reflecting strong global adoption of satellite internet   • Direct-to-Cell Rollout: T-Mobile and SpaceX launched Starlink-powered text messaging service in July, signaling commercialization of direct-to-cell satellite connectivity   • Strategic Spectrum Acquisition: SpaceX acquired $17B worth of wireless spectrum licenses from EchoStar, enabling it to operate independent cellular service without relying on third-party carrier spectrum   • These updates indicate continued vertical integration and expansion of SpaceX’s capabilities across broadband, mobile, and space infrastructure sectors, with strong long-term value creation potential",1972,0.0088,48713.92,2168,0.0020,50011.38,0.0109
2025_09_Q3_-_Figure_AI_(Parkway)_-_Q3_2025_Investor_Update,2.0,"**Quantitative Performance:**   • Net IRR: Not disclosed   • Net MOIC: 6.25x (vs benchmark 1.4x - Top 10%)   • Net DPI: 0.06x (vs benchmark 0.07x - Below Median)   • All Entity (as of Sep 30, 2025): TVPI 6.25x, DPI 0.06x; Current Value $3,499,365,975 on $559,740,900 contributions   • Parkway Fund 3 (Q3 2025): TVPI 6.70x; Fund Value $741,190,393 on $110,635,061   • Parkway Fund 2 (Q3 2025): TVPI 1.03x; DPI 0.13x; Fund Value $63,915,998 on $61,992,384   • Co-Investment 7 (Figure AI): TVPI 51.42x; Current Value $802,975,661 on $15,617,300   • Co-Investment 9 (Figure Series B): TVPI 12.60x; Current Value $1,369,009,292 on $108,661,899   • Co-Investment 3 (OnScale): TVPI 3.89x; DPI 3.80x; Current Value $24,692,604 on $6,350,000","  • Capital Invested: $15.6M   • Current Value: $803.0M   • TVPI: 51.4x   • DPI: 0%   • Capital Invested: $108.7M   • Current Value: $1.37B   • TVPI: 12.6x   • DPI: 0%   • Capital Invested: $85.1M   • Current Value: $84.5M   • TVPI: 0.99x   • DPI: 0%   • Total Parkway exposure to Figure AI across all rounds exceeds $209M, with combined current value over $2.25B, reflecting extremely strong marked appreciation, especially in Series A and B holdings.","**Key Takeaways and Business Updates:**   • No fund-level Net IRR disclosed; only a deal IRR (6%) referenced for Fund 1.   • Aggregate performance driven by concentrated winners: All-entity TVPI 6.25x with low DPI (0.06x) to date.   • Fund 3 is the primary performance driver; Fund 2 has returned meaningful capital via OnScale exit.   • Figure-related co-investments show outsized mark-ups (51.4x and 12.6x), materially boosting NAV.   • Commercial traction highlighted: SandboxAQ nine-figure TCV deals; Persefoni 96% gross retention; TestFit >$5M ARR; R4 DoD contract could double ARR if executed.","  • Public demonstrations of real-world humanoid dexterity, including folding laundry and loading a dishwasher—complex tasks requiring fine motor coordination and perceptual reasoning.   • Completion of a $1B+ Series C round, bringing Figure’s post-money valuation to $40+ billion. Parkway led the round, with strategic participation from NVIDIA, Intel Capital, Qualcomm Ventures, Salesforce, Brookfield, LG, T-Mobile Ventures, Microsoft, OpenAI, and Jeff Bezos.   • Launch of Project Go-Big, a landmark initiative focused on large-scale humanoid pretraining using internet-scale multimodal data and human-to-robot skill transfer.   • Reveal of Figure 03, the next-gen humanoid platform designed for mass production, with modular components, improved battery, and tighter AI integration.   • Figure has gone from a $420M valuation at Series A (2023) to $40B+ in Series C (2025), making it one of the most capital-efficient and rapidly appreciated investments in Parkway’s portfolio.","**Market Commentary:**   • Q3 2025 momentum across Figure AI, SandboxAQ, and TAE Technologies with enterprise deployments, gov’t/defense engagements, and strategic investor support.   • SandboxAQ: multi-year Bahrain partnership expected to accelerate biotech/drug-discovery commercialization.   • Figure AI: scaled rapidly (>$1B Series C; reported $40B+ post-money) and launched Project Go‑Big / Figure 03 iteration.   • TAE Technologies: raised >$150M (Jun 2025) with Google, Chevron, NEA participation; continued strategic backing.   • R4: advancing commercial, city/state, and defense deals including multi‑billion licensing terms under diligence.","  • Figure’s technology integrates proprietary Helix AI, enabling real-world general-purpose functionality in humanoid robots.   • Strategic partnership with Brookfield provides real-world industrial environments for training data and deployment—an edge in large-scale robotics learning.   • Parkway remains a major backer and board-level partner, having led all funding rounds from Series A through C.   • Figure is positioned at the frontier of embodied AI and is explicitly cited alongside OpenAI and xAI in Parkway's commentary on the emerging race toward AGI, with expected near-general cognitive functionality by 2027.",16404,0.0524,48713.92,5321,0.0057,50011.38,0.0581
2025_09_Q3_-_MBX_I_(FRx_Select)_-_Q3_2025_Report,0.0,"**Quantitative Performance:**   • Net IRR: 15.75%   • Net MOIC: 1.61x   • Net DPI: 0.64x   • As of 9/30/2025: Net IRR 15.75%   • As of 9/30/2025: TVPI 1.61x   • As of 9/30/2025: DPI 0.64x   • As of 9/30/2025: MOIC 1.97x   • % of commitments called: 100%   • Portfolio: 20 companies; 17 active; 3 realized + 1 partial   • Realization: Opentrons secondary (Series C) cost $484,067, proceeds $6,716,235 (partial; residual remains)   • Realization: Brightside Health secondary (Series B) cost $800,000, proceeds $3,750,818   • Realization: Osmosis acquired by Elsevier cost $500,000, proceeds $738,299   • Realization: SecureAire acquired by R-Zero cost $500,000, proceeds $0   • Other holdings: FundRx residual value $1,649,998; $46,365 distribution from carried interest on SPV sale","  • MBX Capital III, LP is early in its deployment cycle with 27% of commitments called as of September 30, 2025, four investments closed and five additional investments planned, reflecting an active but still formative portfolio construction phase.   • All closed investments are currently marked at cost, with no unrealized gains or losses reported this quarter, which is typical given the early-stage nature and recency of deployments.   • Fund-level Net IRR, Net MOIC, and Net DPI are not reported this quarter, and no significant distributions are anticipated in the near term.","**Key Takeaways and Business Updates:**   • Fund-level (9/30/2025): Net IRR 15.75%, TVPI 1.61x, DPI 0.64x (MOIC also reported 1.97x)   • Fully called (100%); no further capital calls anticipated   • No material near-term distributions; potential small tax distribution in Q1 2026 from de minimis 2025 proceeds   • Largest realizations: Opentrons ($6.72mm on $0.48mm cost) and Brightside ($3.75mm on $0.80mm cost)   • Write-offs recorded at $0: CareRev ($1.50mm cost), Koneksa ($0.60mm), Luna Care ($0.60mm)","  • Portfolio companies are showing early signs of operating traction, particularly Keebler Health with $4.7M in contracted ARR and Persist AI with $1.3M in YTD bookings, indicating revenue momentum despite conservative valuation marks.   • Juniper Genomics has launched commercially and doubled revenue and clinic adoption quarter-over-quarter, ending Q3 at a $280K annualized revenue run rate, demonstrating initial product-market fit in IVF genetic testing.   • Capital call expectations are front-loaded, with up to 10% anticipated imminently and up to an additional 30% expected in 2026, suggesting an acceleration in deployment aligned with a robust deal pipeline.","**Market Commentary:**   • Fund will not make new company investments; may do follow-ons   • New investments sourced from MBX III with $1–4mm checks   • Management fees deferred to preserve reserves; repayment tied to liquidity   • Lucy Goods projecting $50mm revenue in 2025 (100% YoY); exploring Series C and building factory   • Atlas Labs near breakeven; est. $15.5mm revenue in 2025, $20mm in 2026; gross margin +12% YoY   • AmacaThera signed exclusive Pacira licensing deal up to $230mm; closed bridge financing   • Concert Health forecasting $36mm revenue in 2025 (+58% YoY); may seek financing to reach cash-flow breakeven   • Contraline expecting Phase 2 data publication in NEJM; raising Series B for Phase 3   • Opentrons CEO replaced; $32mm YTD revenue through Q3; recapitalization anticipated with fund evaluating participation   • Mightier pivoting to B2B health-plan sales; targeting >$15mm ARR and breakeven in 2026   • Tvardi Therapeutics went public (NASD: TVRD); position marked to quarter-close price","  • The fund remains focused on early-stage, deep health and biotech investments, targeting pre-seed through Series A rounds with $1–$4M check sizes and emphasizing platform science and differentiated technical risk.   • New and planned investments highlight themes in synthetic biology, AI-driven oncology decision support, microbiome therapeutics, and neurodegeneration, with several deals structured using tranched capital to manage development and execution risk.   • Management notes a strong opportunity pipeline and encourages LP engagement for founder introductions, while also offering year-end 1:1 check-ins to discuss fund progress, outlook, and strategy.",4283,0.0184,48713.92,4174,0.0052,50011.38,0.0237
2025_12_Q4_-_Boram_Care_-_December_2025_Investor_Update,3.0,"**Quantitative Performance:**   • Net IRR: N/A   • Booking sales trend continues to be strong; total sales surpassed $1.5M   • LTV $1,670+   • CAC $355   • First celebrity booking","  • At underwriting in December 2023, Boram was projected to generate ~$2.5M of revenue in 2023 and scale to ~$9.9M in 2025, driven primarily by rapid expansion of Boram Retreats, meaningful contribution from Boram Anywhere (~26% of revenue), and improving gross margins to ~32% with net profitability by 2025. The company has completely pivoted business models, and it is a little too early to tell whether they will succeed; but we consider the company to be underperforming based on its revenue and margin profile.   • s of December 2025, Boram has generated ~$1.54M in cumulative gross booking sales year-to-date and ~$694K in completed (recognized) revenue, materially below original 2025 revenue expectations.   • While top-line scale has underperformed underwriting projections, actual unit-level performance remains strong, with ARPU of ~$8.4K and LTV of ~$1.67K+.   • The business remains cash flow negative at the operating level, with monthly net losses in the ~$65K–$110K range and an end-of-year cash balance of ~$342K, contrasting with underwriting expectations that envisioned net profitability in 2025.","**Key Takeaways and Business Updates:**   • Total sales surpassed $1.5M   • Unit economics: LTV $1,670+ vs. CAC $355   • Cash runway through Feb–March 2026   • Fundraise efforts planned until mid-Jan; targeting a $3M round with a lead or considering a bridge round","  • Revenue realization continues to lag bookings, but the growing pipeline and consistent processed revenue suggest improving conversion efficiency over time.   • Customer acquisition efficiency is compelling given favorable LTV-to-CAC dynamics, which positions the business well for scale once growth capital is secured.   • Management indicated active fundraising efforts through mid-January, evaluating either a $3M priced round with a lead investor or a potential bridge round to extend runway.   • Cash runway is limited to February–March 2026, making near-term fundraising execution critical to avoid operational disruption.",**Market Commentary:**   • Mobile apps (client & creator/partner facing) launching end of Q1   • Fundraising options under evaluation: $3M round with a lead and/or a potential bridge round,"  • Boram plans to launch both client-facing and care professional–facing mobile applications by the end of Q1 2026, which could enhance user experience, engagement, and operational efficiency.   • The company completed its first celebrity booking, signaling growing brand awareness and potential for higher-profile partnerships or demand catalysts.",1357,0.0054,48713.92,2147,0.0023,50011.38,0.0077
2025_11_Q4_-_Coatue_Asia_-_November_2025_Exposure_Report,3.0,"**Quantitative Performance:**   • Net IRR: N/A   • Net MOIC: N/A   • Net DPI: N/A   • Reported fund NAV: USD 552,046,733 (as of 30-Nov-2025)   • CAF return: MTD Gross -4.06%, MTD Net -4.06%, YTD Net 69.03%   • CA Offshore Feeder return: MTD Gross -4.06%, MTD Net -4.06%, YTD Net 69.02%   • Benchmark YTD: MSCI China 30.23%, Hang Seng Tech 25.31%, CSI Overseas China 26.67%, NASDAQ 21.71%   • Portfolio gross contribution by country (long): China -0.89%, Japan -3.16%, Korea -0.78%, Taiwan -0.65%, Other +0.19%, Cash/Other -5.29% (total long -5.29%)   • Portfolio gross contribution by sector (long): Internet -0.20%, Tech -2.61%, Telecom/Media +0.19%, Consumer/Retail -0.14%, Other -2.53% (total long -5.29%)   • AUM (USD mm): CAF 307, CAOFF 244; Total 552   • NAV confirmation: Morgan Stanley USD 378,508,196 (68.57%); Private Placement USD 92,062,464 (16.68%); Goldman USD 75,488,690 (13.67%); Other <2%   • ASC 820 levels: Level I USD 394,503,191 (71.46%); Level II USD 67,181,473 (12.17%); Level III (private) USD 92,062,464 (16.68%)   • Total equity exposure by market cap (% NAV): $1bn–$5bn 2.23%; $5bn–$10bn 8.80%; $10bn–$50bn 10.12%; $50bn–$100bn 3.99%; $100bn–$1tn 10.13%; >$1tn 6.89%; Private 8.42%; Cash/Other 1.23%","  • Fund NAV (as of Nov 30, 2025): $552.0M   • MTD Performance (Net): -4.1%   • YTD Performance (Net): 54%","**Key Takeaways and Business Updates:**   • Reported returns are fund-level but performance shown is for a Class A‑unrestricted investor since 3 Dec 2021 (may be share-class specific).   • YTD net +69.03% materially outperformed listed benchmarks (MSCI China 30.23%, Hang Seng Tech 25.31%, CSI Overseas China 26.67%, NASDAQ 21.71%).   • MTD net was -4.06% (both CAF and feeder).   • NAV concentration: Morgan Stanley custody/counterparty ~68.6% of NAV.   • Level III (private investments) 16.68% of NAV; private placement positions limited liquidity and one private issuer reported.","  • Strong year-to-date performance of ~54% net for both the main and feeder funds contrasts with a sharp MTD decline of -4.1%, primarily attributed to technology and China-related exposures.   • The fund significantly outperformed major indices YTD (e.g., MSCI China Index at 30.2%, Hang Seng Tech Index at 25.3%, NASDAQ Composite at 21.7%).   • The portfolio is heavily concentrated in large-cap and mega-cap names (>$10B in market cap accounts for ~31% of NAV), while small and mid-cap exposures remain limited.   • Exposure by sector remains skewed toward Tech (26.8%), Private (8.4%), and Consumer/Retail (2.1%).   • Geographic concentration remains high with primary exposure to Japan (6.6%), South Korea (20.6%), and Taiwan (8.7%). Notably, China exposure was flat, suggesting hedging or limited active positions in the month.   • Despite the monthly drawdown, the cumulative return chart (page 3) shows positive long-term compounding since inception (Dec 2021), outperforming regional benchmarks.",**Market Commentary:**   • Manager notes one private issuer as of report date.   • Private placement positions have limited liquidity.   • NAV verification uses MSFS confirmations and manager pricing inputs.,"  • As of this report, the fund holds 15 issuers and maintains a high liquidity profile, with 98%–100% liquidity available within 1–5 days.   • Portfolio pricing integrity is supported by third-party confirmations, with 83.3% of NAV independently confirmed by MSFS and 16.7% from fund manager inputs, primarily for private investments.   • Only one private issuer is currently held in the portfolio; these private placement positions have limited liquidity.   • Private investment NAV is classified as Level III under ASC 820 and comprises the largest single issuer exposure (8.42% of NAV), indicating a material position with limited public valuation transparency.   • No leverage or short exposure is indicated in the report; performance is driven by long-only equity and option positions.",4630,0.0188,48713.92,3283,0.0035,50011.38,0.0223
"2025_09_Q3_-_Blue_Sage_Strategic_Credit_Fund,_LP_-_Q3_2025_Quarterly_Letter",3.0,"**Quantitative Performance:**   • Net IRR: N/A (no fund-level Net IRR reported)   • Net MOIC: N/A (no fund-level Net MOIC/TVPI reported)   • Net DPI: N/A (no fund-level Net DPI reported)   • Final closing at approximately $287 million, exceeding hard cap   • As of September 30, 2025, approximately $3 million of total capital called (~1% of total capital available)   • As of September 30, 2025, $3 million called from Private Limited Partners and $0 million from the SBA   • Private capital called to date approximately 3% of private capital   • During Q3, reviewed 63 opportunities, discussed 8 in-depth with the Investment Committee, and entered into 1 Letter of Intent","  • The fund held a final close at approximately $287M, exceeding its hard cap following an accelerated fundraising process.   • As of September 30, 2025, approximately $3M of capital had been called, representing ~1% of total fund capital, all from Private Limited Partners with no SBA capital drawn to date.   • Net IRR, Net MOIC, and Net DPI are not yet available as the fund has not completed its first platform investment and remains in the early deployment phase.","**Key Takeaways and Business Updates:**   • Fund is in early deployment with minimal capital called (~1% of total capital available as of 9/30/2025)   • Fundraising exceeded hard cap with ~ $287 million final close   • No fund-level Net IRR, Net MOIC/TVPI, or Net DPI reported in this update   • First platform investment expected to close year-end 2025 or Q1 2026","  • Deployment discipline is emphasized, with a deliberate pace toward the first platform investment expected around year-end 2025 or Q1 2026.",**Market Commentary:**   • Spencer Klein joined in September as Principal and will serve on the fund’s investment committee (previously at Capital Southwest)   • John Baizer joined in May as Senior Associate (previously at DW Healthcare)   • Team continues to build investment professional talent   • Robust pipeline activity; first platform investment tracking toward year-end or Q1 2026 closing   • Sourcing strategy described as synergistic across the Blue Sage family of funds,"  • The fund strategy focuses on providing debt and equity capital to small, private, lower middle market businesses, often serving as first institutional capital alongside founders and management teams.   • Sector focus includes manufacturing, services, environmental, and industrial markets, consistent with Blue Sage’s historical sourcing strengths.   • Deal activity was robust during the quarter, with 63 opportunities reviewed, eight discussed in depth at the Investment Committee level, and one Letter of Intent executed.   • Team expansion continued with the addition of a Principal (Spencer Klein) and a Senior Associate (John Baizer), enhancing sourcing and underwriting capacity, with further hiring planned.",2205,0.0088,48713.92,2117,0.0020,50011.38,0.0107
"2025_09_Q3_-_MBX_Capital_II,_LP_-_Q3_2025_Report",0.0,"**Quantitative Performance:**   • Net IRR: 3.63%   • Net MOIC: 1.29x   • Net DPI: 0.19x   • Fund-level MOIC: 1.29x (as of 9/30/2025)   • Fund-level TVPI: 1.11x (as of 9/30/2025)   • Fund-level DPI: 0.19x (as of 9/30/2025)   • Fund-level Net IRR: 3.63% (as of 9/30/2025)   • % of commitments called: 85%   • Portfolio: 22 companies; 20 active; 2 realized   • Arine: cost $799,999; current value $2,684,094; closed $21mm net new CARR YTD (total CARR $65mm); burn cut $2.8mm→$0.7mm   • Junction Health: revenue $73K→$306K; appointments 5→178; first site unit-profitable; second site opened   • Mae Health: revenue +20% QoQ to $898K; >750 doula sessions (+26% QoQ)   • OFFOR Health (SmileMD): EBITDA positive; revenue +46% YoY; targeting debt refinance by Q1'26   • Vivodyne: 12 HIVEs deployed; projecting up to $6mm bookings after refocus on ADME/tox   • Realization — Rula (Path CCM): cost $999,996; proceeds $6,417,206 (secondary sale)   • Realization — Vaxxinity: cost $2,000,000; proceeds $157,618 (post-IPO sale)","  • As of September 30, 2025, the fund has called 85% of commitments, holds 22 portfolio companies (20 active, 2 realized), and is largely past initial deployment, with future activity limited to selective follow-ons rather than new platform investments.   • Aggregate fund performance reflects a Net IRR of 3.63%, MOIC of 1.29x, TVPI of 1.11x, and DPI of 0.19x.   • Two realizations to date include a strong outcome in Rula (Path CCM), generating ~$6.4mm of proceeds on ~$1.0mm invested, partially offset by a weak post-IPO exit in Vaxxinity with ~$0.16mm returned on $2.0mm invested.","**Key Takeaways and Business Updates:**   • Fund performance (9/30/2025): Net IRR 3.63%, MOIC 1.29x, TVPI 1.11x, DPI 0.19x   • Capital deployment largely complete; 85% of commitments called   • Limited near-term liquidity; no significant distributions anticipated   • Two realizations: Rula ($6.417mm proceeds on ~$1.0mm cost) and Vaxxinity ($0.158mm proceeds on $2.0mm cost)   • Arine is the primary value driver (current value ~$2.684mm on $0.800mm cost)   • Several companies show execution risk (e.g., Macro Trials, Thesis core brand, Journey Colab winding down)","  • The fund is in the 2nd quartile for Net IRR and Net TVPI for the 2021 vintage.   • It’s in the 1st quartile for DPI.   • Several companies show encouraging operating momentum (e.g., Junction Health reaching unit-level profitability, OFFOR Health remaining EBITDA positive with strong YoY growth, Mae Health scaling revenue and utilization), but many remain capital-raising dependent or behind plan, contributing to overall performance uncertainty.   • The write-off of Journey Colab and uneven outcomes across realized investments highlight continued downside risk, reinforcing that future fund returns hinge on successful financings, clinical milestones, and commercial execution in a concentrated subset of the portfolio.","**Market Commentary:**   • No new company investments from this fund; follow-ons possible for existing portfolio   • New company investments are being done from MBX III with typical checks of $1–4mm   • Anticipated capital calls: up to 10% of commitments over the next year   • Anticipated distributions: none significant in the near term   • Portfolio being managed by outcome category: Probable Contributors, Open Outcomes, Write-offs, Realizations","  • Capital markets remain challenging for early-stage biotech, evidenced by multiple companies actively pursuing large Series A/B rounds (often $30–70mm) with thin cash buffers, extended timelines, and reliance on non-dilutive grants or strategic partnerships.",4390,0.0175,48713.92,3566,0.0042,50011.38,0.0217
2025_09_Q3_-_Thoma_Bravo_-_Q3_2025_Quarterly_Performance_Update_(1),2.0,"**Quantitative Performance:**   • Net IRR: 12.2% (vs benchmark 10.12% - Above Median)   • Net MOIC: 1.34x (vs benchmark 1.18x - Top 25%)   • Net DPI: 0.072x (vs benchmark 0.19x - Below Median)   • Fund NAV (9/30/25): $566.5M   • Total paid-in capital: $438.7M; Distributions: $31.5M (Distributions / PIC: 7.2%)   • Funded commitment less recallable: $388.2M (80.9% of $479.9M commitments)   • Last capital call: 6/23/25, $21.8M (10th call, 4.5% of committed); Last distribution: 12/3/25, $15.6M (3rd distribution, 3.5% of contributed)   • Average age of remaining portfolio: 2.5 years; Underlying Fund XV MOIC 1.40x (82.8% funded; underlying commitments $477.0M; fund size $8.8B)","  • Net IRR: 12.2% (fund level), 12.1% (for a $500K investor)   • Net MOIC: 1.34x (fund level), 1.33x (for a $500K investor)   • Net DPI (Distributions / Paid-in Capital): 7.2%   • NAV (as of 9/30/25): $566.5M   • Total Commitments: $479.9M   • Funded Commitments (net of recallables): $388.2M (80.9%)   • Total Paid-in Capital: $438.7M   • Distributions to Date: $31.5M   • Underlying Fund (Thoma Bravo Fund XV) MOIC: 1.40x (82.8% funded)   • Total Investments: 8, all still unrealized; 1 is publicly traded   • Average Age of Portfolio: 2.5 years",**Key Takeaways and Business Updates:**   • Fund-level performance as of 9/30/25: 12.2% net IRR and 1.34x net MOIC   • Low realized return to date: net DPI of 0.072x (7.2% distributions / paid-in capital)   • Capital largely deployed: 80.9% funded commitment less recallable   • Portfolio is relatively young: 2.5 years average age of remaining investments (as of 9/30/25),"  • Fund performance is tracking steadily with a Net IRR of 12.2% and MOIC of 1.34x, reflecting a solid mark-up across the portfolio   • DPI remains modest at 7.2%, typical for a fund still early in realization phase (vintage 2022, avg. portfolio age 2.5 years)   • Capital deployment is largely complete with over 80% of capital funded, supporting a transition into value build-up and select liquidity events   • The portfolio is fully concentrated in software and IT, with 100% of value in that sector, and 89% of holdings based in the U.S.   • The top 8 positions represent 100% of portfolio value, with largest exposures to SailPoint (18.9%), Ping Identity (17.3%), and Coupa Software (16.1%)   • Net MOIC has steadily increased over time, rising from 0.97x in mid-2022 to 1.34x as of Q3 2025, signaling consistent NAV appreciation","**Market Commentary:**   • Anaplan acquired Syrup Tech (Sep 2025) to expand AI-native retail supply chain forecasting/optimization   • Darktrace closed Mira Security (Q3 2025) to strengthen network traffic visibility and decryption for regulated industries   • Ping Identity’s Procyon (Q2 2025) continues to perform, bolstering workforce access management   • Coupa pursuing revenue acceleration: partnership with Bottomline, disciplined renewal pricing, launch of Coupa Advantage Marketplace   • Bottomline migrating customers to a new Financial Messaging SaaS; R&D prioritizing customer-facing AI capabilities   • Imprivata redesigning sales to improve cross-sell and releasing face authentication and Patient Access products   • Qlik announced Open Lakehouse and an Agentic AI framework (Q2 2025); focused on bookings and cross-sell   • Portfolio: 100% Information Technology; geography 89% U.S., 11% U.K.; top holdings SailPoint 18.9%, Ping 17.3%, Coupa 16.1%","  • Anaplan: Acquired Syrup Tech in September 2025 to enhance AI-native retail supply chain forecasting; continues profitable growth with reinvestment in tech and GTM strategy   • Bottomline Technologies: Migrating customers to new Financial Messaging SaaS platform; investing in AI for accounts payable automation   • Coupa: Pursuing multiple revenue initiatives including payment monetization via Bottomline, supplier upsells, and launch of the Coupa Advantage Marketplace   • Darktrace: Closed acquisition of Mira Security in Q3 to boost network security visibility, especially in encrypted traffic analysis for regulated industries   • Imprivata: Restructuring sales to improve cross-sell efficiency; launching new face authentication and Patient Access identity tools   • Ping Identity: Q2 acquisition of Procyon continues to perform well, strengthening access management capabilities   • Qlik: Released Open Lakehouse and Agentic AI framework; focused on expanding analytics product suite and bookings growth   • These updates reflect a portfolio actively executing on AI, cybersecurity, cloud migration, and enterprise productivity trends through M&A and product expansion",7382,0.0229,48713.92,4268,0.0053,50011.38,0.0281
"2025_09_Q3_-_LEONID_Credit_Income_Fund,_LP_-_Q3_2025_Investor_Update",3.0,"**Quantitative Performance:**   • Net IRR: N/A   • Net MOIC: N/A   • Net DPI: N/A   • Q3 2025 total return: 4.0% net of fees and expenses (based on contributed capital)   • Q3 2025 net cash return: 2.8%   • Time-Weighted Rate of Return (TTM), net: 15.3%; Trailing Twelve Month (TTM) net return: 14.5%   • TTM benchmark comparisons: Preqin Private Credit 8.4% (LCIF +6.1%), CDLI 10.1% (LCIF +4.4%), Morningstar LSTA US Leveraged Loan Index 7.5% (LCIF +7.0%)   • Total LP Managed Capital: $298.8MM; Investor Capital Deployed: $245.7MM; Dry Powder (uncalled): $53.1MM   • Total realizations (ITD): $67.5MM across 53 borrowers","  • 4.0% net total return for Q3 2025, net of fees and expenses, driven by continued capital deployment and strong borrower demand, with 2.8% of the quarter’s return realized in net cash distributions and no reliance on fund-level leverage.   • The underwriting anticipated leverage via a warehouse line as a return enhancer; to date, returns have been achieved with zero fund-level leverage, implying embedded upside to underwriting once leverage ramps toward management’s stated 1:1 target.   • Underwriting targeted ~15% net yield after fees on an unlevered basis, driven by high contractual spreads and rapid capital recycling; Q3 results show a 14.5% TTM net return and 15.3% net TWR, indicating performance is tracking at or slightly above underwritten net return targets, even before the introduction of fund-level leverage.   • Total LP managed capital stood at $298.8 million, with $245.7 million deployed and $53.1 million of remaining dry powder, positioning the Fund for full deployment in early Q4.   • The portfolio consisted of 57 active credit positions, with 100% of borrowers performing and amortizing, 0.0% non-performing exposure, and a minimal 0.4% watch list allocation.   • Portfolio risk metrics remained conservative, including 11.0% loan-to-value against controlled government cash flows, 13.9-month average duration, no fund-level leverage, and maximum borrower concentration of 8.5%, underscoring capital preservation discipline.","**Key Takeaways and Business Updates:**   • Net TTM performance reported at 15.3% (TWR) / 14.5% (TTM net)   • Outperformed cited private credit and leveraged loan benchmarks over the TTM period (Preqin, CDLI, LSTA)   • Credit quality: 100.0% performing & amortizing; 0.0% non‑performing; watch list 0.4% of portfolio   • Portfolio risk: duration 13.9 months; LTV 11.0% against controlled government cash flows   • Concentration: max borrower 8.5% (OnPoint Defense Systems); payor concentration at agency level 5.4% (USAF, AFWERX)   • No leverage currently; plan to draw leveraged facility after full deployment targeting ~1:1 fund-level leverage over time","  • Leonid continues to demonstrate consistent double-digit net returns with low duration and no leverage, validating the strength of its underwriting model and focus on mission-critical, government-backed cash flows.   • Expense efficiency improved materially, with annualized expenses reduced to approximately 81 basis points, representing a more than 50% year-over-year decline.   • The Fund is expected to reach full deployment in early Q4 2025, after which management plans to gradually introduce leverage toward a long-term 1:1 equity-to-debt target to sustain origination velocity and enhance returns.","**Market Commentary:**   • Recent federal shutdown caused administrative delays (invoice processing/contracting); payments normalized after operations resumed   • Investment focus remains on awarded, fully escrowed government contracts to limit shutdown disruption   • Department of War adopting Warfighting Acquisition System (WAS) to compress timelines; increased use of commercial acquisition pathways (CSOs, OTAs)   • Operations hires: Monroe Weng as CFO; Ted Lanes as permanent COO; two FP&A hires added   • Fund administration: working with Ultimus LeverPoint to target 30–45 day reporting window post quarter-end   • Capital deployment expected to be fully deployed within a week (relative to report date); will begin using leverage thereafter   • Tax/expenses: blocker tax estimate increased to $4.2MM (Deloitte); estimated pro forma expense ~22 bps this quarter / ~81 bps annualized; >50% YoY reduction (excl. one‑time items)","  • Leonid strengthened its institutional infrastructure with the appointment of a new CFO, formalization of the COO role, and expanded FP&A capabilities, while accelerating reporting timelines toward a Q+30–45 day standard.   • Management emphasized that the recent U.S. federal government shutdown had no material adverse impact on portfolio performance, as Leonid exclusively finances awarded, escrowed, and mission-critical national-security contracts that continue operating under “excepted activities.”",4920,0.0177,48713.92,4949,0.0071,50011.38,0.0248
2025_12_Q4_-_Merida_Capital_Partners_III_&_IV_-__Message_to_Merida_Investors,3.0,"**Quantitative Performance:**   • Net IRR: No fund-level Net IRR disclosed   • Net MOIC: No fund-level Net MOIC/TVPI disclosed   • Net DPI: No fund-level Net DPI disclosed   • No fund-level Net IRR, Net MOIC/TVPI, or Net DPI disclosed in this update   • Public cannabis equities surged on rumors of the Executive Order, then sold off after announcement; prices remain ~30–40% above pre-rumor levels (since Dec 12) on high volume   • Estimate: ~15 public cannabis companies could each benefit >$100MM/year from removal of IRS 280E (implying >$1.5B aggregate annual cash-flow benefit to large U.S. operators)   • Estimated unpaid 280E tax collections for 2023–2025 potentially $800MM–$1.4B; companies may be able to settle for ""pennies on the dollar"" (per cited estimates)","  • MBX Capital III, LP is early in its deployment cycle with 27% of commitments called as of September 30, 2025, four investments closed and five additional investments planned, reflecting an active but still formative portfolio construction phase.   • All closed investments are currently marked at cost, with no unrealized gains or losses reported this quarter, which is typical given the early-stage nature and recency of deployments.   • Fund-level Net IRR, Net MOIC, and Net DPI are not reported this quarter, and no significant distributions are anticipated in the near term.","**Key Takeaways and Business Updates:**   • Executive Order to reschedule cannabis from Schedule I to Schedule III is the key macro catalyst (pending DEA finalization)   • Removal of IRS 280E could materially increase after-tax cash flows for U.S. operators; commentary cites effective tax rates up to ~75% for dispensary-only operations   • Schedule III could enable pharmacy distribution and insurance reimbursement, expanding normalized access (manager view)   • Medicare/Medicaid-related CBD pilot programs referenced as starting next year / mid-year   • Manager views market pullback as a buying opportunity in public equities over the next 12 months (opinion)","  • Portfolio companies are showing early signs of operating traction, particularly Keebler Health with $4.7M in contracted ARR and Persist AI with $1.3M in YTD bookings, indicating revenue momentum despite conservative valuation marks.   • Juniper Genomics has launched commercially and doubled revenue and clinic adoption quarter-over-quarter, ending Q3 at a $280K annualized revenue run rate, demonstrating initial product-market fit in IVF genetic testing.   • Capital call expectations are front-loaded, with up to 10% anticipated imminently and up to an additional 30% expected in 2026, suggesting an acceleration in deployment aligned with a robust deal pipeline.","**Market Commentary:**   • Manager combining Q3/Q4 update into a single mid-January call due to timing/significance of Executive Order developments   • DEA finalization expected to shift macro behavior positively; potential for pharmacy partnerships with dispensaries to expand medical access   • Pharma may enter via acquisitions rather than building internally, which could re-rate sector valuations if M&A occurs   • Reports cite AG Bondi tasked to implement mandates by end of January; CBD to enter Medicare pilots by mid-year   • Manager references a 2017 ""Size Matters"" commentary for historical perspective","  • The fund remains focused on early-stage, deep health and biotech investments, targeting pre-seed through Series A rounds with $1–$4M check sizes and emphasizing platform science and differentiated technical risk.   • New and planned investments highlight themes in synthetic biology, AI-driven oncology decision support, microbiome therapeutics, and neurodegeneration, with several deals structured using tranched capital to manage development and execution risk.   • Management notes a strong opportunity pipeline and encourages LP engagement for founder introductions, while also offering year-end 1:1 check-ins to discuss fund progress, outlook, and strategy.",3350,0.0128,48713.92,2750,0.0030,50011.38,0.0157
2025_11_Q4_-_Freedom_Biosciences_-_November_2025_Investor_Update,3.0,**Quantitative Performance:**   • Net IRR: No reported data   • Net MOIC: No reported data   • Net DPI: No reported data   • No significant updates,"  • No fund-level IRR, MOIC, or DPI metrics were disclosed in this update.   • Key programs progressing through preclinical and early clinical stages include Free001 (ketamine IV solution) and Free008 (psychedelic therapeutic for cardiovascular and psychiatric use).   • Series B fundraising is underway with a target raise of $30–50M. Lead investor due diligence is in late stages, with $30M to be unlocked upon planned Phase 2 topline data for Free001 and Phase 1a/b data for Free008.   • Additional capital (up to $50M) may support CMC development and Phase 3 (Free001) and Phase 2 (Free008) trial acceleration.",**Key Takeaways and Business Updates:**   • No significant updates,"  • The company has soft commitments for ~15–20% of the Series B round already from insiders and seeks broader early interest to support term sheet negotiations by December 17.   • Free001 Phase 2: Prototyping is near completion for two IV bag options. Development batch testing is planned for early Q1 2026, with Phase 2 study targeted for Q2 2026, contingent on Series B close.   • Free008 Phase 1: Experienced delays due to Chinese regulatory shifts. A new US-based CRO has been secured. Cardiovascular tox work begins next month, with UK Phase 1 trial planned for early 2027.   • Preparing for a Type D meeting with the FDA in early Q1 2026 to determine if Phase 1 trials for Free008 can proceed in the US to gain time efficiency.",**Market Commentary:**   • No significant updates,"  • Strong external validation is seen in industry M&A and positive trial data, including:   • AbbVie’s $1B+ investment in Gilgamesh’s psychedelic drug.   • Atai/Beckley merger and Supernus’ $561M Sage acquisition.   • Compass Pathways’ and Atai’s positive Phase 2b readouts.   • Freedom Bio was active across several high-profile industry events and conferences:   • 8th Neuropsychiatric Drug Development Conference (Boston).   • One Mind Festival (Napa) – selected participant.   • Wilson Sonsini Biopharma Summit and Wells Fargo Private Track.   • Panel participation at Harvard Business School Healthcare Conference with Gilgamesh and others.   • Upcoming presentations at Evercore, Citi, Lucid, and JPM Healthcare Conferences signal continued engagement with top-tier investors and strategic partners.",1065,0.0029,48713.92,1751,0.0018,50011.38,0.0047
2025_09_Q3_-_Star_Mountain_Fund_-_Q3_2025_Quarterly_Update_(1),1.0,"**Quantitative Performance:**   • Net IRR: 13.8%   • Net MOIC: 1.54x   • Net DPI: 0.16x   • Q3 2025 net: DPI 0.16x, RVPI 1.37x, TVPI 1.54x; Net IRR 13.8% (9/30/25)   • Total gross assets: $324.0M; total invested capital $331M (114% of AUM)   • SBA debenture drawn / facility: $175M / $175M; leverage ratio 0.54x debt-to-assets; fund-level leverage averaged 0.60x   • Yield to maturity: 14.1%; avg spread to SOFR 8.9%; 100% floating (avg floor 1.2%)   • Non-accruals: 2 positions (~5% of total invested); annualized non-accrual rate 0.7%   • Six realizations (through 9/30/25): avg gross IRR 62.2%; net unleveraged IRR 51.2%; illustrative net 0.60x leveraged IRR 98.7%   • Q3 FV change QoQ: +$0.1M; total fund FV = 96.5% of cost","  • Net IRR: 13.8%   • Net TVPI (Total Value to Paid-In): 1.54x   • Net RVPI (Residual Value to Paid-In): 1.37x   • Net DPI (Distributions to Paid-In): 0.16x   • Fund Size: $291M (inclusive of LP, GP, and ABL)   • LP Capital Commitments: $113M, with 85% called ($96M)   • Gross Capital Invested: $331M (reflects redeployment to optimize IRR and MOIC)   • Total Gross Assets: $324M   • SBA Leverage Drawn: $175M (fully drawn facility)   • Leverage Ratio: 0.54x debt-to-total assets   • Average Yield to Maturity (YTM): 14.1%   • Average Cash Interest: 9.9%   • Portfolio Composition: 75% 1st lien debt, 24% 2nd lien/preferred equity, <1% common equity","**Key Takeaways and Business Updates:**   • Net fund performance (9/30/25): 13.8% Net IRR, 1.54x TVPI (net), 0.16x DPI   • Q3 2025 included a 2.3% return of capital distribution; no income distribution under READ   • SBA leverage fully drawn ($175M); 10-year fixed pricing noted ~4.5% (Q3 2025)   • Capital protection: 100% of portfolio companies have covenants; avg maintenance test ~4.2x   • Weighted average internal risk rating 2.7; two investments on non-accrual (Project Heat; Project Peanut II)   • Realizations and returns are preliminary/unaudited; unrealized values marked to market (ASC 820)","  • Consistent NAV and return growth: The fund achieved a net TVPI of 1.54x, up from 1.45x in Q2, reflecting strong unrealized gains despite limited DPI   • Net IRR of 13.8% reflects healthy risk-adjusted performance, especially given conservative underwriting and moderate leverage   • Diversified portfolio of 29 companies with median operating history of 27 years and average EBITDA of $12M, indicating stability in lower middle market exposure   • High embedded value: 83% of portfolio companies include structured equity or warrants; 97% have board observer rights; 100% include financial covenants   • Distributions remain modest, with an 8% average cash distribution yield since inception but only 2.3% return of capital in Q3 2025 due to SBA regulatory constraints on distributions (READ-related)   • Recent realizations (e.g. Project Justice) delivered outsized returns (net IRR: 149.9% leveraged; 290.9% with equity exposure), highlighting upside potential in structured deals","**Market Commentary:**   • READ positive as of Q3 2025; distribution constraints require SBA consent for capital >2% of Regulatory Capital   • No new platform investments closed in Q3 2025; internal risk ratings increased QoQ (partial exit/downgrade drivers)   • Project Justice: debt exited July 2025; retained ~3% equity, strong operating growth (revenue +128% YoY; adj. EBITDA +145% YoY)   • Project Cardinal and Project Sleep showing material YoY growth; Project Quant and Project Federal showing notable declines with active remediation   • Portfolio composition (6/30/25): ~75% 1st lien, ~24% 2nd lien/senior holdco PIK/structured-preferred","  • Project Justice Exit (Q3 2025):  – Provider of adjudication services aligned with the No Surprises Act  – Realized through a refinancing; generated a 5.99x gross MOIC and 178.5% net unleveraged IRR, with further upside remaining via retained equity (valued at ~$121M)  – Notable growth from $10M to $150M EBITDA at exit; Star Mountain played an active board and strategic role in growth   • Post-Q3 Exit: Project Payment (Nov 2025):  – IT staffing and analytics platform; exited via debt refi  – 23.1% gross IRR, 16.5% net unleveraged IRR  – Exit followed strategic add-ons led by Star Mountain, including $34M of incremental funding   • Quarterly Valuation Movements:  – Total fund FV flat QoQ; top write-up was Project Justice (+$5.9M)  – Largest write-down was Project Federal (-$3.8M) due to restructuring in government contracting sector   • Portfolio Highlights:  – Strong YoY growth in investments like Project Android (+145% EBITDA), Project Cardinal (+35% EBITDA), and Project Sleep (+28% EBITDA)  – Continued challenges in Project Quant (-49% EBITDA) and Project Federal (-74% EBITDA), although management changes and AI initiatives are underway   • Risk Ratings:  – Portfolio quality remains stable with 75% rated 1–3, implying no anticipated impairment  – Slight increase in average risk rating due to one downgrade (Project Metal) and the exit of a high-performing asset   • Leverage Management:  – SBA leverage usage is moderate and consistent (average 0.60x over fund life), with fixed rate borrowings at 4.5% average cost",30327,0.0901,48713.92,5470,0.0046,50011.38,0.0947
